Company
AboutTeamImpact
Science
Development ModelFocus AreasPipeline
Partnering
Business ModelPartners
Proof
Case StudiesContact
Home / About

Why Off Targets.

A specialty pharmaceutical company built on known molecules, engineered into differentiated products, with the structure and discipline to deliver them.

Investment Thesis

A structurally advantaged category — not a trend.

Complex injectables and differentiated formulations sit in a part of the pharmaceutical market with real, durable structural advantages — independent of any single product's performance.

COMPLEXITY PREMIUM

A Structurally Protected Market

Sterile and complex-injectable manufacturing carries real barriers — regulatory compliance, capital intensity, and technical difficulty — that keep these markets meaningfully less crowded than standard generics. The same complexity that slows new entrants protects margin for the companies that can execute.

CAPITAL EFFICIENCY

A Fraction of the Cost, a Fraction of the Time

Full new chemical entity development is commonly cited at roughly $2.6 billion and 10 to 15 years. Development built on known molecules under defined regulatory pathways is typically a small fraction of that capital and timeline — years, not a decade; tens of millions, not billions.

TAILWIND

A Widening Opportunity Set

A significant wave of injectable and complex-drug patent expirations over the next several years is expanding the pool of molecules with established safety profiles and open commercial opportunity — a structural tailwind independent of any single product's performance.

Global Operations

A two-hub operating model.

Operations spanning the United Kingdom and India combine scientific expertise, regulatory strategy, intellectual property planning, and commercial insight under one team.

HUB 01 — UNITED KINGDOM

Business & Regulatory Gateway

Business Development · Licensing · IP Strategy

Leads global business development and licensing negotiations, intellectual property strategy, and regulatory positioning across UK and EU markets — the commercial front door for partners and investors.

HUB 02 — INDIA, BANGALORE

R&D Laboratory

Owned Facility · 50+ Scientists

Our own state-of-the-art R&D laboratory — the scientific engine of the pipeline, executing formulation, analytical, and preclinical development day to day.

Extended Technology Access — via academic partner network, on a need basis
Genomics & Sequencing

Next-generation and single-cell sequencing, Sanger sequencing, digital PCR

Structural Biology

Cryo-electron microscopy, NMR spectroscopy, X-ray micro-CT

Mass Spectrometry

Proteomics, metabolomics & lipidomics, biologics characterization

Advanced Microscopy

Confocal & super-resolution imaging, scanning & transmission electron microscopy

High-Throughput Screening

High-content imaging, flow cytometry analysis & sorting

Microfabrication & Models

3D printing, microfluidics, transgenic animal models

Next step

Discuss a program, licence or collaboration.